Skip to main content

Table 7 Studies describing hospital costs or charges in patients with resistant and multidrug-resistant Pseudomonas aeruginosa infections

From: Clinical and economic consequences of hospital-acquired resistant and multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author Study groups (n) Description of cost Hospital Inpatient Care Costs or Charges Reported P-value Ref
Main findings
Eagye et al. (2009) Meropenem resistant P. aeruginosa (58) Median total cost (IQR) $100,704 ($27,710 – $183,125) < 0.001 [53]
Meropenem susceptible P. aeruginosa (125) $32,594 ($13,112 – $100,702)
Meropenem resistant P. aeruginosa (58) $100,704 ($27,710 – $183,125) < 0.001
Control (57) $25,744 ($17,456 – $40,616)
Evans et al. (2007) Susceptible P. aeruginosa (73) Median total cost (IQR) $99,672 ($43,714 – $187,260 0.015 [71]
Resistant P. aeruginosaa (47) $69,502 ($24,853 – $113,933)
Gasink et al. (2006) Fluoroquinolone resistant P. aeruginosa (320) Median total charges (IQR)* $62,325 ($22,129 - $188,979) 0.008 [64]
Fluoroquinolone susceptible P. aeruginosa (527) $48,733 ($18,760 - $124,820)
Lautenbach et al. (2010) Imipenem resistant P. aeruginosa (253) Mean hospital cost after culture sampling (95% CI) $286,417 ($234,326 – $338,510) < 0.001 [63]
Imipenem susceptible P. aeruginosa (2289) $189,274 ($172,428 – $206,121)
Morales et al. (2012) MDR P. aeruginosab (134) Mean hospital cost after culture sampling (median) $13,178 ($5,745) < 0.001 [49]
Susceptible P. aeruginosa (149) $4,258 ($2,420)
Resistant P. aeruginosa (119) $10,662 ($5,248) < 0.001
Susceptible P. aeruginosa (149) $4,258 ($2,420)
  1. *Hospital charges reported after identification of infection with P. aeruginosa; P-value reported for mean length of stay; aAbsence of susceptibility to all the drugs in one or more of the following antibiotic classes: aminoglycosides, cephalosporins, carbapenems, and fluoroquinolones; bAbsence of susceptibility to carbapenems, β-lactams, quinolones, tobramycin, and gentamicin.